IDEAYA Biosciences Hits Day High with 7.28% Surge Amid Financial Struggles

IDEAYA Biosciences, Inc. has experienced a notable increase of 7.28% on September 18, 2025, reaching an intraday high of USD 26.43. This small-cap company operates within the Pharmaceuticals & Biotechnology sector and currently holds a market capitalization of USD 2,050 million.
Despite today's positive movement, IDEAYA has faced significant challenges in its financial performance. The company has reported negative results for the last nine consecutive quarters, with an operating cash flow of USD -293.7 million, marking a concerning low. Additionally, the return on capital employed (ROCE) stands at -35.09%, indicating inefficiencies in generating returns from its capital investments.

The pre-tax profit for the most recent quarter was USD -77.49 million, reflecting a decline of 46.84%. Over the past year, IDEAYA has underperformed the broader market, generating a return of -31.85%, while the S&P 500 has seen gains of 17.72%. With a negative EBITDA and a debt-to-equity ratio of -0.70, the company continues to navigate a challenging financial landscape.